Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innate Pharma S.A. (IPHA) SEC filings page on Stock Titan provides access to the company’s US regulatory submissions, primarily filed as a foreign private issuer on Form 6-K and Form 20-F-related documents. Innate Pharma is a global, clinical-stage biotechnology company developing antibody-based immunotherapies for cancer, with securities listed on Euronext Paris (IPH) and Nasdaq (IPHA).
Through these filings, Innate Pharma reports information that supplements its press releases and investor communications. Form 6-K reports typically furnish press releases on topics such as business updates, clinical trial progress, financial results, changes in capital structure, and key corporate developments. Some 6-K filings are incorporated by reference into Innate Pharma’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
For a company focused on immuno-oncology and antibody-engineering, SEC filings can provide additional detail on collaboration and licensing agreements with partners such as Sanofi and AstraZeneca, risk factor discussions, and descriptions of pipeline assets including IPH4502, lacutamab, monalizumab and ANKET®-based programs. Filings may also include information on share capital, voting rights, financing tools such as at-the-market programs, and other capital markets activities.
On Stock Titan, these documents are complemented by AI-powered summaries designed to help readers quickly understand the key points of lengthy filings. Users can review new Form 6-K submissions as they are furnished to the SEC’s EDGAR system, and use the summaries to navigate complex regulatory language, while still having access to the full original documents for detailed analysis.
Innate Pharma S.A. reports its capital and voting structure as of December 31, 2025. The Company had 93,719,323 ordinary shares outstanding, along with 6,324 Preferred Shares 2016 and 7,581 Preferred Shares 2017. Based on French market rules, Innate calculates a total of 94,484,443 theoretical voting rights, which includes all shares with attached voting rights, even those suspended, and incorporates voting rights from AGAP 2016. The number of exercisable voting rights, which excludes treasury shares with suspended rights, was 94,465,868. The Company also highlights its focus on developing next-generation immunotherapies for cancer and notes collaborations with major partners such as AstraZeneca and Sanofi.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
